Soft Tissue Sarcoma - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
244 Pages - GMD12033
$2,000.00

Summary

Global Markets Direct’s, ‘Soft Tissue Sarcoma - Pipeline Review, H1 2014’, provides an overview of the Soft Tissue Sarcoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Soft Tissue Sarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Soft Tissue Sarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Soft Tissue Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Soft Tissue Sarcoma Overview 10
Therapeutics Development 11
Pipeline Products for Soft Tissue Sarcoma - Overview 11
Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis 12
Soft Tissue Sarcoma - Therapeutics under Development by Companies 13
Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes 16
Soft Tissue Sarcoma - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Soft Tissue Sarcoma - Products under Development by Companies 21
Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes 23
Soft Tissue Sarcoma - Companies Involved in Therapeutics Development 24
Amgen Inc. 24
Eli Lilly and Company 25
GlaxoSmithKline plc 26
Merck & Co., Inc. 27
Novartis AG 28
Pfizer Inc. 29
Cell Therapeutics, Inc. 30
Exelixis, Inc. 31
A. Menarini Industrie Farmaceutiche Riunite Srl 32
Celgene Corporation 33
Bayer AG 34
EntreMed, Inc. 35
Oncolytics Biotech Inc. 36
Topotarget A/S 37
CytRx Corporation 38
Threshold Pharmaceuticals, Inc. 39
MabVax Therapeutics, Inc. 40
Nanobiotix SA 41
Morphotek, Inc. 42
GP Pharm, S.A. 43
MolMed S.p.A. 44
Pharma Mar, S.A. 45
TRACON Pharmaceuticals, Inc. 46
Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. 47
Recombio 48
Polaris Group 49
Karyopharm Therapeutics, Inc. 50
Activartis Biotech GmbH 51
Soft Tissue Sarcoma - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 57
Assessment by Route of Administration 61
Assessment by Molecule Type 64
Drug Profiles 67
ridaforolimus - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
aldoxorubicin - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
TH-302 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
trabectedin - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
N-glycolyl-GM3/Very Small Size Proteoliposome Vaccine - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
regorafenib - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
sabarubicin - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
sunitinib malate - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
brostallicin - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
ENMD-2076 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
panobinostat - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
ganitumab - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
belinostat - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
everolimus - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
cabozantinib s-malate - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
NGR-hTNF - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
pelareorep - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
ontuxizumab - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Angiotensin 1-7 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Sarcoma Vaccine - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
pazopanib hydrochloride - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
trabectedin - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
doxorubicin liposomal - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
AL-3818 - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
olaratumab - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
paclitaxel albumin-bound - Drug Profile 139
Product Description 139
Mechanism of Action 139
R&D Progress 139
New Castle Disease Virus - HUJ Oncolytic Virus - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
ONCOS-102 - Drug Profile 142
Product Description 142
Mechanism of Action 142
R&D Progress 142
NBTXR-3 - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
TRC-105 - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
AV0-113 - Drug Profile 147
Product Description 147
Mechanism of Action 147
R&D Progress 147
KPT-330 - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 148
TNF-PEG 20 - Drug Profile 150
Product Description 150
Mechanism of Action 150
R&D Progress 150
NOV-110501 - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
NBTX-TOPO - Drug Profile 152
Product Description 152
Mechanism of Action 152
R&D Progress 152
NBTXR-3 - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
Soft Tissue Sarcoma - Recent Pipeline Updates 155
Soft Tissue Sarcoma - Dormant Projects 231
Soft Tissue Sarcoma - Discontinued Products 232
Soft Tissue Sarcoma - Product Development Milestones 233
Featured News & Press Releases 233
Mar 31, 2014: CytRx Receives Orphan Medicinal Product Designation from the European Commission for Aldoxorubicin in Soft Tissue Sarcoma 233
Mar 27, 2014: CytRx Issues Statement Regarding Recent Lawsuits 234
Mar 24, 2014: CytRx Initiates Pivotal Global Phase 3 Clinical Trial with Aldoxorubicin for Second-Line Treatment of Soft Tissue Sarcoma 234
Feb 03, 2014: TRACON Pharmaceuticals Initiates Phase 1b Study of TRC105 in Patients With Advanced Soft Tissue Sarcoma 235
Jan 21, 2014: CytRx Receives FDA Approval to Extend Aldoxorubicin Dosing Cycles until Disease Progression in Upcoming Pivotal, Global Phase 3 Trial for Soft Tissue Sarcomas 236
Jan 08, 2014: CytRx Reports Additional Analyses Supporting Highly Statistically Significant Positive Results from Global Phase 2b Clinical Trial with Aldoxorubicin in Advanced Soft Tissue Sarcomas 237
Jan 08, 2014: BioSpecifics Technologies Corp. Announces Positive Top-line Data from Phase 2 Clinical Trial of CCH for the Treatment of Human Lipoma 239
Dec 30, 2013: Threshold Pharmaceuticals Announces Target Enrollment of 620 Patients Achieved in Pivotal Phase 3 Trial of TH-302 in Advanced Soft Tissue Sarcoma 239
Dec 11, 2013: CytRx Reports Highly Statistically Significant Positive Results from its Global Phase 2b Clinical Trial 240
Dec 10, 2013: CytRx to Hold Conference Call December 11, 2013 at 10:30 a.m. Eastern Time to Discuss Results of Global Phase 2b Clinical Trial with Aldoxorubicin versus Doxorubicin as First-Line Therapy in Advanced Soft Tissue Sarcomas 242
Appendix 243
Methodology 243
Coverage 243
Secondary Research 243
Primary Research 243
Expert Panel Validation 243
Contact Us 244
Disclaimer 244

List of Tables
Number of Products under Development for Soft Tissue Sarcoma, H1 2014 11
Number of Products under Development for Soft Tissue Sarcoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Comparative Analysis by Unknown Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Development by Companies, H1 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2014 23
Soft Tissue Sarcoma - Pipeline by Amgen Inc., H1 2014 24
Soft Tissue Sarcoma - Pipeline by Eli Lilly and Company, H1 2014 25
Soft Tissue Sarcoma - Pipeline by GlaxoSmithKline plc, H1 2014 26
Soft Tissue Sarcoma - Pipeline by Merck & Co., Inc., H1 2014 27
Soft Tissue Sarcoma - Pipeline by Novartis AG, H1 2014 28
Soft Tissue Sarcoma - Pipeline by Pfizer Inc., H1 2014 29
Soft Tissue Sarcoma - Pipeline by Cell Therapeutics, Inc., H1 2014 30
Soft Tissue Sarcoma - Pipeline by Exelixis, Inc., H1 2014 31
Soft Tissue Sarcoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2014 32
Soft Tissue Sarcoma - Pipeline by Celgene Corporation, H1 2014 33
Soft Tissue Sarcoma - Pipeline by Bayer AG, H1 2014 34
Soft Tissue Sarcoma - Pipeline by EntreMed, Inc., H1 2014 35
Soft Tissue Sarcoma - Pipeline by Oncolytics Biotech Inc., H1 2014 36
Soft Tissue Sarcoma - Pipeline by Topotarget A/S, H1 2014 37
Soft Tissue Sarcoma - Pipeline by CytRx Corporation, H1 2014 38
Soft Tissue Sarcoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 39
Soft Tissue Sarcoma - Pipeline by MabVax Therapeutics, Inc., H1 2014 40
Soft Tissue Sarcoma - Pipeline by Nanobiotix SA, H1 2014 41
Soft Tissue Sarcoma - Pipeline by Morphotek, Inc., H1 2014 42
Soft Tissue Sarcoma - Pipeline by GP Pharm, S.A., H1 2014 43
Soft Tissue Sarcoma - Pipeline by MolMed S.p.A., H1 2014 44
Soft Tissue Sarcoma - Pipeline by Pharma Mar, S.A., H1 2014 45
Soft Tissue Sarcoma - Pipeline by TRACON Pharmaceuticals, Inc., H1 2014 46
Soft Tissue Sarcoma - Pipeline by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., H1 2014 47
Soft Tissue Sarcoma - Pipeline by Recombio, H1 2014 48
Soft Tissue Sarcoma - Pipeline by Polaris Group, H1 2014 49
Soft Tissue Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 50
Soft Tissue Sarcoma - Pipeline by Activartis Biotech GmbH, H1 2014 51
Assessment by Monotherapy Products, H1 2014 52
Number of Products by Stage and Target, H1 2014 55
Number of Products by Stage and Mechanism of Action, H1 2014 59
Number of Products by Stage and Route of Administration, H1 2014 63
Number of Products by Stage and Molecule Type, H1 2014 66
Soft Tissue Sarcoma Therapeutics - Recent Pipeline Updates, H1 2014 155
Soft Tissue Sarcoma - Dormant Projects, H1 2014 231
Soft Tissue Sarcoma - Discontinued Products, H1 2014 232

List of Figures
Number of Products under Development for Soft Tissue Sarcoma, H1 2014 11
Number of Products under Development for Soft Tissue Sarcoma - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 52
Number of Products by Top 10 Target, H1 2014 53
Number of Products by Stage and Top 10 Target, H1 2014 54
Number of Products by Top 10 Mechanism of Action, H1 2014 57
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 58
Number of Products by Top 10 Route of Administration, H1 2014 61
Number of Products by Stage and Top 10 Route of Administration, H1 2014 62
Number of Products by Top 10 Molecule Type, H1 2014 64
Number of Products by Stage and Top 10 Molecule Type, H1 2014 65

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax